Reinhart Partners LLC. Has $9.09 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Reinhart Partners LLC. reduced its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 7.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 80,305 shares of the medical equipment provider's stock after selling 6,450 shares during the period. Reinhart Partners LLC.'s holdings in Zimmer Biomet were worth $9,089,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dorsey & Whitney Trust CO LLC increased its position in shares of Zimmer Biomet by 2.3% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock valued at $485,000 after acquiring an additional 102 shares during the last quarter. M&T Bank Corp increased its position in shares of Zimmer Biomet by 0.4% during the 4th quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock worth $2,834,000 after purchasing an additional 108 shares during the last quarter. MGO One Seven LLC increased its position in shares of Zimmer Biomet by 5.1% during the 4th quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider's stock worth $238,000 after purchasing an additional 110 shares during the last quarter. FWG Holdings LLC raised its stake in shares of Zimmer Biomet by 3.5% during the 4th quarter. FWG Holdings LLC now owns 3,715 shares of the medical equipment provider's stock worth $402,000 after purchasing an additional 124 shares in the last quarter. Finally, Erste Asset Management GmbH boosted its holdings in shares of Zimmer Biomet by 0.3% in the 4th quarter. Erste Asset Management GmbH now owns 41,487 shares of the medical equipment provider's stock valued at $4,434,000 after buying an additional 124 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Trading Up 0.6%

ZBH stock opened at $92.47 on Friday. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $116.71. The company has a market capitalization of $18.30 billion, a PE ratio of 20.78, a price-to-earnings-growth ratio of 1.95 and a beta of 0.72. The company's 50-day simple moving average is $97.95 and its 200 day simple moving average is $104.14. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. During the same quarter in the previous year, the firm posted $1.94 EPS. The business's revenue for the quarter was up 1.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 annualized dividend and a yield of 1.04%. Zimmer Biomet's dividend payout ratio is presently 21.24%.

Analyst Ratings Changes

Several research firms have issued reports on ZBH. Stifel Nicolaus set a $115.00 price target on shares of Zimmer Biomet and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Barclays reduced their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a report on Monday, February 10th. Canaccord Genuity Group dropped their price objective on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. Finally, JPMorgan Chase & Co. reduced their target price on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of "Hold" and a consensus price target of $111.53.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.